Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, USA.
Drug Metab Dispos. 2012 Apr;40(4):706-16. doi: 10.1124/dmd.111.043158. Epub 2012 Jan 6.
Cryopreserved human hepatocytes suspended in human plasma (HHSHP) have previously provided accurate CYP3A drug-drug interaction (DDI) predictions from a single IC(50) that captures both reversible and time-dependent inhibition. The goal of this study was to compare the accuracy of DDI predictions by a protein-free human hepatocyte system combined with the fraction unbound in plasma for inhibitor(s) with those obtained with protein-containing incubations. Seventeen CYP3A, CYP2C9, or CYP2D6 inhibitors were incubated with hepatocytes in human plasma or hepatocyte maintenance medium (HMM) for 20 min over a range of concentrations after which midazolam 1'-hydroxylation, diclofenac 4'-hydroxylation or (R)-bufuralol 1'-hydroxylation were used to quantify the corresponding cytochrome P450 (P450) catalytic activities. Two methods were used to predict the human exposure ratio of the victim drug in the presence and absence of inhibitor. The HMM K(i, app) values were combined with the free average systemic plasma concentration ("free [I] with HMM K(i, app)") and the plasma K(i, app) values were combined with the total average systemic plasma concentration ("total [I] with plasma K(i, app)"). Of 63 clinical DDI studies, the total [I] with plasma K(i, app) method predicted 89% of cases within 2-fold of the reported interaction whereas the free [I] with HMM K(i, app) method predicted only 59%. There was a general underprediction by the free [I] with HMM K(i, app) method, which is consistent with an underestimation of in vitro inhibition potency in this system. In conclusion, the HHSHP system proved to be a simple, accurate predictor of DDIs for three major P450s and superior to the protein-free approach.
冷冻保存的人肝细胞混悬于人血浆(HHSHP)中,以前曾通过单个 IC50 提供准确的 CYP3A 药物相互作用(DDI)预测,该 IC50 同时捕获了可逆和时间依赖性抑制。本研究的目的是比较无蛋白人肝细胞系统与血浆中游离部分抑制剂(s)相结合,预测 DDI 的准确性与含蛋白孵育获得的结果。在一系列浓度下,将 17 种 CYP3A、CYP2C9 或 CYP2D6 抑制剂与人血浆或肝细胞维持培养基(HMM)中的肝细胞孵育 20 分钟,然后使用咪达唑仑 1'-羟化、双氯芬酸 4'-羟化或(R)-布他洛尔 1'-羟化来定量相应的细胞色素 P450(P450)催化活性。使用两种方法预测在存在和不存在抑制剂的情况下,受影响药物在人体内的暴露比。将 HMM K(i,app) 值与游离平均系统血浆浓度(“用 HMM K(i,app) 的游离[I]”)结合,将血浆 K(i,app) 值与总平均系统血浆浓度(“用血浆 K(i,app) 的总[I]”)结合。在 63 项临床 DDI 研究中,“用血浆 K(i,app) 的总[I]”方法预测了 89%的报告相互作用在 2 倍以内的病例,而“用 HMM K(i,app) 的游离[I]”方法仅预测了 59%。“用 HMM K(i,app) 的游离[I]”方法存在普遍的低估,这与该系统中体外抑制效力的低估一致。总之,HHSHP 系统被证明是三种主要 P450 药物相互作用的简单、准确预测因子,优于无蛋白方法。